Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Discover Emerging Technologies Driving the Future of Global Markets (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News Alpha Tau Medical Ltd DRTS

Alternate Symbol(s):  DRTSW

Healthcare Biotechnology
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical... see more

Recent & Breaking News (NDAQ:DRTS)

Alpha Tau Announces FDA Approval of IDE Supplement to Expand Pilot Trial of Alpha DaRT® to Thirty Patients with Pancreatic Cancer in Two Cohorts, with Locally Advanced or Metastatic Disease

GlobeNewswire February 3, 2025

Alpha Tau Announces Cornerstone Interim Data Across Multiple Clinical Trials to be Shared at R&D Update Day

GlobeNewswire January 27, 2025

Alpha Tau Announces Upcoming Presentation of New Data at 2025 ASCO GI Symposium and at Company R&D Update Day

GlobeNewswire December 18, 2024

Alpha Tau Announces Appointment of Maya Netser to its Board of Directors; Board Member Meir Jakobsohn Stepping Down, Staying on as Advisor

GlobeNewswire December 17, 2024

Alpha Tau to Present at the 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewswire December 11, 2024

Alpha Tau to Participate in Ladenburg's Oncology Innovators & Investors Symposium

GlobeNewswire December 6, 2024

Alpha Tau Medical Announces Third Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire November 19, 2024

Alpha Tau to Participate in Citi's 2024 Global Healthcare Conference and Piper Sandler's 36th Annual Healthcare Conference

GlobeNewswire November 13, 2024

Alpha Tau Announces Acceptance Into FDA's Total Product Life Cycle Advisory Program to Accelerate Market Access to Alpha DaRT® for Patients with Recurrent Glioblastoma Multiforme

GlobeNewswire October 21, 2024

Alpha Tau Treats First Patient with Recurrent Lung Cancer

GlobeNewswire October 10, 2024

Alpha Tau Announces FDA Approval of IDE to Initiate Multi-Center Investigator-Initiated Study of Alpha DaRT® in Immunocompromised Patients with Recurrent cSCC

GlobeNewswire September 20, 2024

Sidoti Events, LLC's Virtual September Small-Cap Conference

ACCESS Newswire September 17, 2024

Alpha Tau to Participate in the H.C. Wainwright 26th Annual Global Investment Conference, the Sidoti Small-Cap Virtual Investor Conference, the Redburn Atlantic and Rothschild & Co 2024 Radiopharma Conference, and the Lytham Partners Fall 2024 Investor Conference

GlobeNewswire August 22, 2024

Alpha Tau Medical Announces Second Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire August 14, 2024

Alpha Tau Announces Publication in Cancers Journal of Long-Term Safety and Efficacy Data in Multiple Hard-to-Treat Superficial Cancers

GlobeNewswire June 25, 2024

Alpha Tau to Present at the Jefferies Global Healthcare Conference

GlobeNewswire May 21, 2024

Alpha Tau Medical Announces First Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire May 20, 2024

Alpha Tau Announces Alpha DaRT Treatment of First Patient with Liver Metastases of Colorectal Cancer

GlobeNewswire May 13, 2024

Alpha Tau Presents Preclinical Data Demonstrating Abscopal Immune Effect in Pancreatic Murine Tumor Models at ESTRO 2024 Congress in Glasgow

GlobeNewswire May 6, 2024

Alpha Tau to Participate in May Investor Conferences

GlobeNewswire May 1, 2024

Podcasts